

CLAIMS

1. A method for expanding $\gamma\delta$ T cells, wherein said method comprises the steps of:
 - (i) preparing a composition enriched for $\gamma\delta$ T cells; and
 - (ii) culturing the composition in the presence of feeder cells, wherein the feeder cells are present in a ratio of at least 4:1 (feeder cells : $\gamma\delta$ T cells), and wherein the feeder cells are derived from skin.
2. A method for expanding $\gamma\delta$ T cells, wherein said method comprises the steps of:
 - (i) preparing a composition enriched for $\gamma\delta$ T cells; and
 - (ii) culturing the composition in the presence of feeder cells and media comprising IL-15 and IL-21, wherein the feeder cells are present in a ratio of at least 3:2 (feeder cells : $\gamma\delta$ T cells), and wherein the feeder cells are derived from skin.
3. A method for expanding $\gamma\delta$ T cells, wherein said method comprises the steps of:
 - (i) preparing a composition enriched for $\gamma\delta$ T cells by depletion of $\alpha\beta$ T cells; and
 - (ii) culturing the composition in the presence of feeder cells, wherein the feeder cells are present in a ratio of at least 3:2 (feeder cells : $\gamma\delta$ T cells), and wherein the feeder cells are derived from skin.
4. The method according to any one of claims 1 to 3, wherein the feeder cells are present in a ratio of at least 4:1 (feeder cells : $\gamma\delta$ T cells).
5. The method according to any one of claims 1 to 4, wherein the feeder cells are present in a ratio of about 10:1 to about 99:1 (feeder cells : $\gamma\delta$ T cells).
6. The method according to any one of claims 1 to 5, wherein the feeder cells comprise $\alpha\beta$ T cells.
7. The method according to claim 6, wherein the $\alpha\beta$ T cells comprise CD4 T cells, Natural Killer (NK) cells, or both CD4 T cells and NK cells.
8. The method according to any one of claims 1 to 7, wherein the feeder cells are irradiated.

9. The method according to any one of claims 1 to 8, wherein:
 - (i) the feeder cells are derived from a single donor;
 - (ii) the $\gamma\delta$ T cells are derived from a single donor; or
 - (iii) both (i) and (ii).
10. The method according to any one of claims 1 to 9, wherein the feeder cells and the $\gamma\delta$ T cells are derived from the same donor(s).
11. The method according to any one of claims 1 to 10, wherein the method comprises removing the feeder cells from the expanded $\gamma\delta$ T cells by (i) depletion of $\alpha\beta$ T cells or (ii) positive selection of $\gamma\delta$ T cells.
12. The method according to any one of claims 1 to 11, wherein: (a) step (i) comprises depletion of $\alpha\beta$ T cells from a mixed cell population obtained from a starting sample; or (b) step (i) comprises positive selection of $\gamma\delta$ T cells from a mixed cell population obtained from a starting sample.
13. The method according to claim 12, wherein the starting sample is skin.
14. The method according to any one of claims 1 to 11, wherein the composition is cultured in media comprising IL-15, IL-21, or both IL-15 and IL-21.
15. The method according to any one of claims 13 or 14, wherein the media additionally comprises IL-2 and/or IL-4
16. The method according to any one of claims 1 to 15, wherein the method comprises culturing the composition for between 7 and 21 days.
17. The method according to any one of claims 1 to 16, wherein expanding the population of $\gamma\delta$ T cells provides at least a 5-fold number of $\gamma\delta$ T cells.
18. The method according to any one of claims 1 to 17, wherein the method comprises freezing the expanded $\gamma\delta$ T cells.

19. An expanded $\gamma\delta$ T cell population obtainable, such as obtained, by the method of any one of claims 1 to 18.
20. A pharmaceutical composition comprising the expanded $\gamma\delta$ T cell population according to claim 19.
21. Use of the expanded $\gamma\delta$ T cell population according to claim 19 or the pharmaceutical composition according to claim 20 in the manufacture of a medicament for the treatment of cancer.